Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
Abstract Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) variability. This study aimed to develop and externally validate a multicentric, population PK (PopPK) model for intrave...
Main Authors: | Khalil Ben Hassine, Tiago Nava, Yves Théoret, Christa E. Nath, Youssef Daali, Nastya Kassir, Victor Lewis, Robbert G. M. Bredius, Peter J. Shaw, Henrique Bittencourt, Maja Krajinovic, Chakradhara Rao Satyanarayana Uppugunduri, Marc Ansari |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12683 |
Similar Items
-
Economic Impact of Pharmacokinetic Monitoring on the use of Oral and Intravenous Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
by: Karpen, Stephen, et al.
Published: (2014) -
The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation
by: Chakradhara Rao S. Uppugunduri, et al.
Published: (2017-07-01) -
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
by: Nishihori Taiga, et al.
Published: (2010-10-01) -
Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.
by: Joy Benadiba, et al.
Published: (2018-01-01) -
Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use
by: Vid Mlakar, et al.
Published: (2016-09-01)